Metabolic pathway

SkinMedica® Launches Even & Correct

Retrieved on: 
Tuesday, January 17, 2023
Dark, Cream, Melasma, Hyperpigmentation, Face, PIH, LTN, Dermatology, Collection, Senior, NYSE, Phytochemical, ABBV, Tranexamic acid, Titanium metallic discoloration, Patient, Metabolic pathway, John Foster Dulles, Physician, Science, Serum, AbbVie, MSRP, Skin discoloration, Cosmetics, Nicotinamide, Correctness

IRVINE, Calif., Jan. 17, 2023 /PRNewswire/ -- Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announces the launch of the long-awaited SkinMedica® Even & Correct Collection. Clinically proven and formulated to deliver targeted results, these three products work separately and together to even skin tone and reduce the appearance of hyperpigmentation and dark spots on the face: Advanced Brightening Treatment, Dark Spot Cream, and Brightening Treatment Pads.

Key Points: 
  • The SkinMedica® Even & Correct products are hydroquinone-free, well tolerated, and effective on all skin types and for multiple ethnicities.
  • SkinMedica® Even & Correct Dark Spot Cream: A heavy-duty, targeted, fast-acting spot treatment booster that minimizes the look of dark spots.
  • SkinMedica® Even & Correct Brightening Treatment Pads: Alcohol-free brightening pads exfoliate and help reduce the appearance of dullness and uneven tone and texture.
  • SkinMedica® Even & Correct Advanced Brightening Treatment ($178 MSRP), SkinMedica® Even & Correct Dark Spot Cream ($88 MSRP), and SkinMedica® Even & Correct Brightening Treatment Pads ($60 MSRP) are available for purchase at SkinMedica.com , and through a network of licensed physicians and medically supervised spas.

SetPoint Medical Announces $80M Preferred Stock Financing to Advance Company’s Novel Treatment for Autoimmune Diseases

Retrieved on: 
Thursday, January 19, 2023
Health, Medical Devices, Health Technology, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Degenerative disease, New Enterprise Associates, NEA, Vagus nerve stimulation, Metabolic pathway, Boston Scientific, Norwest Venture Partners, General partnership, Neck, Immunosuppression, FDA, Viking Global Investors, Risk, Food and Drug Administration, Richard King Mellon, Association of British HealthTech Industries, Partnership, Food, Rheumatoid arthritis, Patient, Morgenthaler, RA, Inflammation, Vagus nerve, Inflection point, Stage 2, Pharmaceutical industry, Medical device, Norwest

SetPoint Medical , a clinical-stage healthcare company dedicated to patients with chronic autoimmune diseases, today announced an $80 million preferred stock financing co-led by new investors Norwest Venture Partners and Viking Global Investors.

Key Points: 
  • SetPoint Medical , a clinical-stage healthcare company dedicated to patients with chronic autoimmune diseases, today announced an $80 million preferred stock financing co-led by new investors Norwest Venture Partners and Viking Global Investors.
  • The company is developing its novel platform for the treatment of chronic, inflammation-mediated autoimmune diseases and is initially focused on a potentially less immunosuppressive option for the treatment of rheumatoid arthritis (RA).
  • “Over the past two decades, advancements in biologic therapies have had a significant impact on the treatment of autoimmune diseases.
  • “SetPoint is uniquely positioned with a novel approach to treating autoimmune diseases by activating innate neural pathways that work to reduce inflammation.

Lauded Neurosurgeon, Researcher and Inventor Nicholas Theodore, MD Joins Harvard MedTech’s Medical Advisory Board

Retrieved on: 
Tuesday, January 10, 2023
Mental Health, Medical Devices, Health, Surgery, Research, Science, Brain, Algorithm, Metabolic pathway, Mike Donlin, Depression, Johns Hopkins, Anxiety, Barrow Neurological Institute, DARPA, Defense, MD, Department of Defense Serum Repository, Harvard University, Johns Hopkins School of Medicine, Spine, Patient, Research, FACS, Neurosurgery, Carnegie Center for Art & History, Surgical Innovation, Pain management, Medtech, Pain, Pharmaceutical industry, Medical device, Medical imaging

Nationally recognized neurosurgeon Nicholas Theodore, MS, MD, FAANS, FACS has accepted an invitation to join the Medical Advisory Board of Harvard MedTech , announced Gerry Stanley, M.D., Chief Medical Officer at Harvard MedTech.

Key Points: 
  • Nationally recognized neurosurgeon Nicholas Theodore, MS, MD, FAANS, FACS has accepted an invitation to join the Medical Advisory Board of Harvard MedTech , announced Gerry Stanley, M.D., Chief Medical Officer at Harvard MedTech.
  • Theodore is the Director of the Neurosurgical Spine Program at the most prestigious neurosurgical program in the country,” noted Dr. Stanley.
  • “In addition to his surgical innovations and research endeavors, Dr. Theodore holds over 20 patents for medical devices and procedures.
  • The purpose of the Harvard MedTech Medical Advisory Board is to facilitate industry-wide adoption of Vx® Therapy in the treatment of workplace trauma.

Divine Spark Coaching Expands HypnoCoaching - a Groundbreaking Approach to Personal Development

Retrieved on: 
Wednesday, December 28, 2022
Mental health, Anxiety, Cognitive behavioral therapy, CBT, Pain, RTT, NLP, Insomnia, Smoking, Knowledge, Depression, COVID-19, Neuro, Mary Morrissey, Growth, Trauma, Metabolic pathway, Drinking, Medicine, Tutoring

New York, New York--(Newsfile Corp. - December 28, 2022) - Divine Spark Coaching is proud to launch its unique HypnoCoaching personal development package which helps clients get unstuck.

Key Points: 
  • New York, New York--(Newsfile Corp. - December 28, 2022) - Divine Spark Coaching is proud to launch its unique HypnoCoaching personal development package which helps clients get unstuck.
  • Charles West, the president and CEO of Divine Spark Coaching, has been studying and applying spiritual principles for over 17 years now.
  • Through Divine Spark Coaching's programs, hundreds of people have seen dramatic results that last well beyond the coaching sessions themselves.
  • To find out more about this coaching or to schedule a complimentary discovery session, visit their website at https://divinesparkcoaching.net/

Click Therapeutics Shares 2022 Accomplishments and Development Progress in its Prescription Digital Therapeutics Programs

Retrieved on: 
Friday, December 23, 2022
Data Management, Biotechnology, Alternative Medicine, Technology, Health, Pharmaceutical, Oncology, Neurology, Health Technology, Software, Clinical Trials, Chills, The New England Journal of Medicine, Information technology, Multiple sclerosis, Partnership, Boehringer Ingelheim, Neuroscience, Click, Massachusetts Medical Society, FAAN, IP, Food, Irritable bowel syndrome, Therapy, DWA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, MD, MMS, Research, Rheumatoid arthritis, Smartphone, Probability, Dynamo, Breast, HIV disease progression rates, Diabetic neuropathy, Invention, Digital, R, Disease, Patient, Medicine, Neurology, Data analysis, Intellectual property, Physician, Inflammation, Schizophrenia, Metabolic pathway, Patent, Fibromyalgia, Doctor of Philosophy, Pharmaceutical industry, Medical imaging, Migraine, Modulation

Click Therapeutics, Inc. (“Click”), a leader in Digital Therapeutics™ as prescription medical treatments, today shared multiple accomplishments and advances in its research and development (R&D) programs.

Key Points: 
  • Click Therapeutics, Inc. (“Click”), a leader in Digital Therapeutics™ as prescription medical treatments, today shared multiple accomplishments and advances in its research and development (R&D) programs.
  • Click’s DiNaMo program develops and evaluates digital mechanisms of action targeted to one or more neural pathways implicated in disease expression.
  • The DiNaMo program was conceptualized, developed, and validated at Click by a multidisciplinary team with backgrounds in neuroscience, serious gaming, medicine, and mobile application development.
  • Click completed enrollment and study assessments for two randomized, controlled, fully decentralized DiNaMo studies in 2022.

Free Webinar - Learning Differences, Brain Trauma, or is it something else?

Retrieved on: 
Tuesday, January 3, 2023
Hand, Trauma, Education, CISD, Tactical Combat Casualty Care, Metabolic pathway, Rehabilitation, Brain, Student, PPCS, Government budget balance, Brain damage, University, Barnstable Academy, Emergency department, Fusion Academy, USAMRMC, Quantitative electroencephalography, TBI, FDA, Traumatic brain injury, Adolescence, Concussion, Physical medicine and rehabilitation, University of Pittsburgh, Virginia Commonwealth University, MPH, Parent, Pittsburgh, FEG, Hack, Science, MS, Head injury, Research, Peak Performance Project, Department of Defense Education Activity, Management, Medical imaging, Medicine, Nature, MD, Neurological disorder, Neurosurgery

GRAND RAPIDS, Mich., Jan. 3, 2023 /PRNewswire/ -- Fusion Education Group will host a free webinar with Neurologics which will help families better understand that traumatic brain injuries are repairable, and the potential recovery paths available to children. A recent study found that 1 in 4 children who suffered a minor head injury are likely to suffer from chronic post-concussion syndrome.

Key Points: 
  • "The science around brain injury is promising," said Fusion Education Group Chief Executive Officer Peter Ruppert.
  • Families are encouraged to register for the webinar to discover if the trauma from a head injury is impacting their student's learning.
  • Odell-Barber and Hack will help parents gain a better understanding of brain trauma and repair through accurate assessment.
  • About Neurologics : Headquartered in Southern California, Neurologics is an innovative and highly effective brain function assessment and optimization company utilizing FDA-registered technology and proprietary software.

Celldex Therapeutics Presents Positive Data from Barzolvolimab Phase 1b Study in Chronic Inducible Urticaria at Global Urticaria Forum 2022

Retrieved on: 
Tuesday, December 6, 2022
Allergy, Hives, Skin temperature, WBC, ET, UCT, Fever, Consultant, Kinetics, Research, COVID-19, Wound healing, GUF, Judgement, B cell, Omalizumab, Phase II, Cancer, Skin, Knowledge, Risk, Hematology, Senior, Therapy, Annual report, Metabolic pathway, Hypersensitivity, Temperature, Dress, SCF, Exercise, Immune system, Disease, Safety, Patient, KIT, Cell, Intellectual property, Tryptase, Inflammation, AES, Angioedema, Form 10-K, Common, Survival, ID, Cold urticaria, Aluminium, Pharmaceutical industry, Tanning (leather), Vaccine, Copper

HAMPTON, N.J., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced new data from the Company’s open label Phase 1b clinical trial of barzolvolimab in patients with antihistamine refractory chronic inducible urticarias are being presented at the GA²LEN Global Urticaria Forum (GUF) held in Berlin, Germany. These diseases, which are often severe and debilitating, can significantly impact patients’ lives. Barzolvolimab is a humanized monoclonal antibody that binds the receptor tyrosine kinase KIT with high specificity and potently inhibits its activity.All 9 of 9 (100%) cold urticaria patients who received a 1.5 mg/kg single full dose of barzolvolimab experienced a complete response as assessed by provocation testing, including 4 of 4 patients with omalizumab refractory disease. This cohort was added to the Phase 1b trial in patients with chronic inducible urticaria after Celldex previously reported a 95% complete response rate in July 2021 in patients with antihistamine-refractory cold urticaria and symptomatic dermographism who received a single 3.0 mg/kg dose of barzolvolimab.

Key Points: 
  • ET -
    HAMPTON, N.J., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced new data from the Company’s open label Phase 1b clinical trial of barzolvolimab in patients with antihistamine refractory chronic inducible urticarias are being presented at the GA²LEN Global Urticaria Forum (GUF) held in Berlin, Germany.
  • A randomized, double-blind, placebo-controlled, multi-dose Phase 2 subcutaneous study of barzolvolimab is currently enrolling patients with both cold urticaria and symptomatic dermographism.
  • Cold Urticaria 1.5 mg/kg intravenous cohort oral presentation: “Cold urticaria patients achieve complete response with 1.5 mg/kg barzolvolimab”
    10 patients received a single intravenous infusion of barzolvolimab at 1.5 mg/kg.
  • Additional Presentations: Encore presentations reviewing previously presented data from the Phase 1b study in chronic spontaneous urticaria and on wound healing are also being presented at GUF.

Former US Sec. of Veterans Affairs & Daughter Launch Chronic Pain Care Startup, Override, Raise $3.5M, Acquire Leading Pain Coaching Company

Retrieved on: 
Thursday, December 15, 2022
Start-Up, Physical Therapy, Technology, Professional Services, Managed Care, Health, General Health, Pharmaceutical, Mental Health, Other Technology, Hospitals, President Trump, Pain, Confluence, Mount Sinai Beth Israel, Veteran, Chronic pain, Patient, Communication, Psychotherapy, Research, Injection, Family, Harvard Law School, Metabolic pathway, Surgeon, Cabinet, Health, Pain scale, Pain management, Nervous system, Dentistry, Medicine, Health insurance, Veterans' affairs, Override

Shortly after fundraising, Override acquired the countrys leading pain management coaching business: Take Courage Coaching.

Key Points: 
  • Shortly after fundraising, Override acquired the countrys leading pain management coaching business: Take Courage Coaching.
  • Override is a non-opioid solution that bridges the gaps in traditionally fragmented, one-size-fits-none chronic pain treatment.
  • Override is a virtual, one-stop-shop that matches patients with a team of chronic pain specialists in pain medicine, physical therapy, and behavioral health.
  • While attending school and building a career, Jennie has struggled to find adequate care for her own complex chronic pain syndrome.

Accenture Invests in BehaVR to Help Expand Access to Mental and Behavioral Healthcare Using Virtual Reality

Retrieved on: 
Tuesday, December 13, 2022
Security, Telemedicine, Virtual Medicine, Data Management, Other Health, Technology, Apps, Applications, Mental Health, General Health, Artificial Intelligence, Metaverse, Other Technology, Software, Networks, Health, Mobile, Wireless, Therapy, Culture, Creativity, VR, Patient, NYSE, Pain, University of Oxford, Virtual reality, Metabolic pathway, Mental health, Health care, Operation, Multimedia, Signals intelligence operational platforms by nation, Anxiety, Fear, Advanced technology, Video game console, Pharmaceutical industry, Medicine, Accenture

Accenture (NYSE: ACN) has made a strategic investment, through Accenture Ventures , in BehaVR , a leading innovator in virtual reality (VR) digital wellness and digital therapeutics experiences.

Key Points: 
  • Accenture (NYSE: ACN) has made a strategic investment, through Accenture Ventures , in BehaVR , a leading innovator in virtual reality (VR) digital wellness and digital therapeutics experiences.
  • View the full release here: https://www.businesswire.com/news/home/20221213005174/en/
    Accenture has made a strategic investment, through Accenture Ventures, in BehaVR, a leading innovator in virtual reality (VR) digital wellness and digital therapeutics experiences.
  • (Photo: Business Wire)
    On the same day, BehaVR announced a merger with OxfordVR , a spin-out of Oxford University and a leader in science-based virtual reality treatments for serious mental illnesses.
  • Its suite of clinically validated therapeutics offer access to treatments on a spectrum across mental wellness and mental and behavioral conditions, including validated treatments for serious mental illness.

Better Therapeutics Completes Exploratory Trial for Fatty Liver Disease and Announces Positive Topline Results

Retrieved on: 
Thursday, December 8, 2022
Health Technology, Health, Clinical Trials, Mental Health, Proton, NAFLD, Therapy, Patient satisfaction, Security (finance), Physician, Webcast, MD, Non-alcoholic fatty liver disease, Biomarker, Patient, NASH, PDT, Cognitive behavioral therapy, Classification, Research, Disease, FDA, Magnetic resonance imaging, Type 2 diabetes, Metabolic pathway, CMO, Behavior, Liver disease, Diet, Degenerative disease, App Store (iOS/iPadOS), CBT, Brain, Health, Marketing, Principal, Better, Insurance, Fatty liver disease, Risk, Dietary supplement, Medical imaging, Pharmaceutical industry

(NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing cognitive behavioral therapy (CBT) to address the root causes of cardiometabolic diseases, today announced positive topline results of the first-ever study evaluating the feasibility of using a prescription digital therapeutic to reduce liver fat and improve liver disease biomarkers in Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH).

Key Points: 
  • (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing cognitive behavioral therapy (CBT) to address the root causes of cardiometabolic diseases, today announced positive topline results of the first-ever study evaluating the feasibility of using a prescription digital therapeutic to reduce liver fat and improve liver disease biomarkers in Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH).
  • With approximately 90 million Americans affected by NAFLD, fatty liver disease is a public health crisis that has hit epidemic levels.
  • The encouraging early results from our work with fatty liver disease continues to build that body of evidence, said Mark Berman, MD, CMO of Better Therapeutics.
  • Better Therapeutics is a prescription digital therapeutics (PDT) company developing a novel form of cognitive behavioral therapy (CBT) to address the root causes of cardiometabolic diseases.